Session » Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Psoriatic Arthritis

Date: Monday, November 13, 2023

Time: 2:00PM-3:30PM

Meeting: ACR Convergence 2023

Abstract Number: 1639

PsA Patients of Diverse Ethnic and Racial Backgrounds Experience More Skin Psoriasis, Increased Pain, and Higher Rates of Radiographic Axial Disease

Abstract Number: 1640

Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network

Abstract Number: 1641

The Window of Opportunity in Psoriatic Arthritis: Similar to Rheumatoid Arthritis?

Abstract Number: 1642

Identifying Distinct Phenotypes in Psoriatic Arthritis: A Study from the Psoriatic Arthritis Research Consortium (PARC) Cohort

Abstract Number: 1643

Exploring the Serum Metabolome for Potential Diagnostic Markers of Psoriatic Arthritis

Abstract Number: 1644

The EISER Study: Identifying Microbial Factors Associated with Subclinical Gut Inflammation in Spondyloarthritis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.